My
Myovant Sciences
Basel CHFounded 2016400 employees
Private CapbiotechAcquiredUrologyOncology
Platform: GnRH Antagonist
Market Cap
N/A
All Drugs
2
Clinical Trials
4
Failed / Terminated
2
FDA Approved
1
Drug Pipeline (2 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Olpazumab | MYO-7539 | Approved | 2 | CD19 | Ewing Sarcoma | ||
| Bemazumab | MYO-6679 | Phase 2/3 | 2 | IL-17A | RBMeso |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (4)